<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg"/></p>
<p>Strive 的訴訟是製藥行業與配藥藥房之間激烈鬥爭的最新一例。oleschwander via Shutterstock.com。</p>
<p>一家美國配藥藥房起訴了禮來和諾和諾德，指控他們阻礙患者獲得複合減肥藥物的機會。</p>
<p>Strive 配藥藥房表示，這些在胰高血糖素樣肽-1 受體激動劑（GLP-1RA）市場占主導地位的製藥公司正在進行 “協調努力，以壓制競爭並限制患者獲得合法複合 GLP-1RA 藥物的機會”。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Eli Lilly and Co 的 LY-3556050</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>NPVM: Novo Nordisk AS 的 LAI-287 + Semaglutide</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現有效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>這起 訴訟 於美國德克薩斯州西區地方法院提起，指控禮來和諾和諾德利用其市場主導地位破壞配藥藥房行業。文件強調了製藥公司與遠程醫療提供商簽署的獨家合作伙伴關係，以便與配藥行業競爭。它還指出，禮來和諾和諾德在過去一年內建立了自己的在線藥房，通過直接面向消費者（DTC）現金渠道以折扣價提供品牌 GLP-1RA。</p>
<p>通過這些聯盟、在線 DTC 平台和明顯的營銷策略，Strive 指控禮來和諾和諾德的行為 “非法限制了競爭，並直接傷害了美國的 GLP-1RA 患者。”</p>
<p>諾和諾德的一位發言人告訴《製藥技術》： “本次訴訟中的指控毫無依據，我們將積極在法庭上進行辯護。諾和諾德始終致力於與監管機構和執法部門合作，確保患者能夠獲得安全、有效且經過 FDA 批准的治療選擇，並保護患者免受未獲批准的仿製藥物的重大安全風險。”</p>
<p>禮來的一位發言人告訴《製藥技術》： “Strive 的訴訟在事實和法律上都是錯誤的，試圖將焦點轉移到其自身行為上。禮來已起訴 Strive，指控其將未經批准的大規模複合產品宣傳為臨牀證明和 “個性化” 的，FDA 和聯邦法院現在都表示這些説法是虛假和誤導的。我們期待在法庭上回應 Strive。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預見？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報的信息</p>
<p>Strive 的訴訟是製藥行業與 配藥藥房之間激烈鬥爭的最新一例。 複合藥物是根據處方定製的非品牌藥物，含有與市場上藥物相同的活性成分，例如諾和諾德的 semaglutide 或禮來的 tirzepatide。根據美國食品藥品監督管理局（FDA）的規定，商業可用藥物短缺是允許複合生產的標準之一。</p>
<p>在 2024 年，禮來的 Mounjaro/Zepbound 和諾和諾德的 Wegovy/Ozempic 短缺期間，複合 GLP-1RA 的使用激增。對許多患者來説，這些版本的一個額外好處是，當時它們的價格遠低於品牌藥物。然而，隨着供應鏈的穩定，FDA 不再允許複合 GLP-1RA 的生產。這是儘管外包設施協會提起的訴訟，最終 被美國地區法官駁回。FDA 專員 Marty Makary宣佈了對非法 GLP-1RA 複合藥物的打擊 在 2025 年 10 月。</p>
<p>諾和諾德在 2025 年中與 Hims &amp; Hers 建立了合作關係，但在幾天後 終止了該合作，指控該遠程醫療平台 “未能遵守法律”。</p>
<p>禮來和諾和諾德已經對幾家在線供應商、健康水療中心和遠程醫療平台提起訴訟，指控它們製造其品牌的 GLP-1 受體激動劑的複合版本。</p>
<p>在本週的摩根大通醫療會議上，諾和諾德的首席執行官 Maziar Mike Doustdar 估計，大約有 150 萬美國患者正在使用其 GLP-1 受體激動劑的複合版本。他指責這些複合藥物製造商針對那些更看重價格的消費者。複合藥物行業的存在是為了提供個性化的藥物版本，而不是更便宜的替代品。</p>

<p>Strive Compounding Pharmacy 已對禮來和諾和諾德提起訴訟，指控這兩家公司在 GLP-1RA 市場上壓制競爭，以限制患者獲得複方藥物的機會。訴訟稱，禮來和諾和諾德利用其市場主導地位，通過獨家合作伙伴關係和自有在線藥房來削弱複方藥房的業務。兩家公司均否認這些指控，聲稱 Strive 的主張毫無依據，並表示他們致力於患者安全。此案突顯了製藥行業與複方藥房之間持續的緊張關係</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg"/></p>
<p>Strive’s lawsuit is the latest in a fierce battle between the pharma industry and compounding pharmacies. oleschwander via Shutterstock.com.</p>
<div class="lb-trans"><p>Strive 的訴訟是製藥行業與配藥藥房之間激烈鬥爭的最新一例。oleschwander via Shutterstock.com。</p>
</div><p>An American compounding pharmacy has sued Eli Lilly and Novo Nordisk for allegedly stifling patient access to compounded weight loss medications.</p>
<div class="lb-trans"><p>一家美國配藥藥房起訴了禮來和諾和諾德，指控他們阻礙患者獲得複合減肥藥物的機會。</p>
</div><p>Strive Compounding Pharmacy said that the drugmakers, who dominate the glucagon-like peptide-1 receptor agonist (GLP-1RA) market, are engaging in a “coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1RA medications”.</p>
<div class="lb-trans"><p>Strive 配藥藥房表示，這些在胰高血糖素樣肽-1 受體激動劑（GLP-1RA）市場占主導地位的製藥公司正在進行 “協調努力，以壓制競爭並限制患者獲得合法複合 GLP-1RA 藥物的機會”。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Eli Lilly and Co's LY-3556050</h4>
<div class="lb-trans"><h4>NPVM: Eli Lilly and Co 的 LY-3556050</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>NPVM: Novo Nordisk AS's LAI-287 + Semaglutide</h4>
<div class="lb-trans"><h4>NPVM: Novo Nordisk AS 的 LAI-287 + Semaglutide</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現有效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The lawsuit, filed in the United States District Court for the Western District of Texas, alleges that Lilly and Novo used their dominant market positions to undermine the compounding pharmacy industry. The document highlights exclusive partnerships that the pharma companies signed with telehealth providers in efforts to compete with the compounding sector. It also points to Lilly and Novo establishing their own online pharmacies in the past year, which offer branded GLP-1RAs via direct-to-consumer (DTC) cash channels at a discounted price.</p>
<div class="lb-trans"><p>這起 訴訟 於美國德克薩斯州西區地方法院提起，指控禮來和諾和諾德利用其市場主導地位破壞配藥藥房行業。文件強調了製藥公司與遠程醫療提供商簽署的獨家合作伙伴關係，以便與配藥行業競爭。它還指出，禮來和諾和諾德在過去一年內建立了自己的在線藥房，通過直接面向消費者（DTC）現金渠道以折扣價提供品牌 GLP-1RA。</p>
</div><p>Through these alliances, online DTC platforms, and apparent marketing strategies, Strive alleges that Lilly and Novo’s conduct “unlawfully restricted competition and directly harmed GLP-1RA patients in the United States.”</p>
<div class="lb-trans"><p>通過這些聯盟、在線 DTC 平台和明顯的營銷策略，Strive 指控禮來和諾和諾德的行為 “非法限制了競爭，並直接傷害了美國的 GLP-1RA 患者。”</p>
</div><p>A Novo spokesperson told <em>Pharmaceutical Technology</em>: “The claims in this litigation are without merit, and we will vigorously defend against them in court. Novo Nordisk remains committed to working alongside regulators and law enforcement to ensure that patients have access to safe, effective, and FDA-approved treatment options and to protect patients from unapproved knockoff drugs that pose significant risks to patient safety.”</p>
<div class="lb-trans"><p>諾和諾德的一位發言人告訴《製藥技術》： “本次訴訟中的指控毫無依據，我們將積極在法庭上進行辯護。諾和諾德始終致力於與監管機構和執法部門合作，確保患者能夠獲得安全、有效且經過 FDA 批准的治療選擇，並保護患者免受未獲批准的仿製藥物的重大安全風險。”</p>
</div><p>A Lilly spokesperson told <em>Pharmaceutical Technology</em>: “Strive’s lawsuit is wrong, on both the facts and law, and an attempt to shift focus away from its own conduct. Lilly sued Strive for advertising its unapproved, mass-compounded products as clinically proven and “personalized,” and both FDA and a federal court have now said that those kinds of statements are false and misleading. We look forward to responding to Strive in court.”</p>
<div class="lb-trans"><p>禮來的一位發言人告訴《製藥技術》： “Strive 的訴訟在事實和法律上都是錯誤的，試圖將焦點轉移到其自身行為上。禮來已起訴 Strive，指控其將未經批准的大規模複合產品宣傳為臨牀證明和 “個性化” 的，FDA 和聯邦法院現在都表示這些説法是虛假和誤導的。我們期待在法庭上回應 Strive。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預見？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報的信息</p>
</div><p>Strive’s lawsuit is the latest in a fierce battle between the pharma industry and compounding pharmacies. Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as Novo’s semaglutide or Lilly’s tirzepatide, pursuant to a prescription. A shortage of a commercially available drug is one of the criteria that allows compounded production, as per US Food and Drug Administration (FDA) regulation.</p>
<div class="lb-trans"><p>Strive 的訴訟是製藥行業與 配藥藥房之間激烈鬥爭的最新一例。 複合藥物是根據處方定製的非品牌藥物，含有與市場上藥物相同的活性成分，例如諾和諾德的 semaglutide 或禮來的 tirzepatide。根據美國食品藥品監督管理局（FDA）的規定，商業可用藥物短缺是允許複合生產的標準之一。</p>
</div><p>The use of compounded GLP-1RAs surged during shortages of Lilly’s Mounjaro/Zepbound and Novo’s Wegovy/Ozempic in 2024. An added benefit for many patients was that these versions were far cheaper than the branded counterparts at the time.  However, with supply chains now stabilised, the FDA no longer allows compounded GLP-1RA production. This was despite a lawsuit by the Outsourcing Facilities Association, which ultimately ended up being dismissed by a US district judge. FDA commissioner Marty Makary announced a clamp down on illegal GLP-1RA compounders in October 2025.</p>
<div class="lb-trans"><p>在 2024 年，禮來的 Mounjaro/Zepbound 和諾和諾德的 Wegovy/Ozempic 短缺期間，複合 GLP-1RA 的使用激增。對許多患者來説，這些版本的一個額外好處是，當時它們的價格遠低於品牌藥物。然而，隨着供應鏈的穩定，FDA 不再允許複合 GLP-1RA 的生產。這是儘管外包設施協會提起的訴訟，最終 被美國地區法官駁回。FDA 專員 Marty Makary宣佈了對非法 GLP-1RA 複合藥物的打擊 在 2025 年 10 月。</p>
</div><p>Novo entered into a partnership with Hims &amp; Hers in mid-2025 but terminated it just days later after accusing the telehealth platform of “failing to adhere to the law”.</p>
<div class="lb-trans"><p>諾和諾德在 2025 年中與 Hims &amp; Hers 建立了合作關係，但在幾天後 終止了該合作，指控該遠程醫療平台 “未能遵守法律”。</p>
</div><p>Lilly and Novo have already taken several online vendors, wellness spas, and telehealth platforms to court for making compounded versions of their branded GLP-1RAs.</p>
<div class="lb-trans"><p>禮來和諾和諾德已經對幾家在線供應商、健康水療中心和遠程醫療平台提起訴訟，指控它們製造其品牌的 GLP-1 受體激動劑的複合版本。</p>
</div><p>Speaking at the J.P. Morgan Healthcare Conference this week, Novo’s CEO, Maziar Mike Doustdar, estimated that around 1.5 million US patients are using compounded versions of its GLP-1RAs. He accused compounders of targeting consumers who prioritised price. The compounded sector exists to provide personalised versions of drugs, rather than cheaper alternatives.</p>
<div class="lb-trans"><p>在本週的摩根大通醫療會議上，諾和諾德的首席執行官 Maziar Mike Doustdar 估計，大約有 150 萬美國患者正在使用其 GLP-1 受體激動劑的複合版本。他指責這些複合藥物製造商針對那些更看重價格的消費者。複合藥物行業的存在是為了提供個性化的藥物版本，而不是更便宜的替代品。</p>
</div>

Compounder sues Lilly and Novo for suppressing GLP-1RA competition

Pharmaceutical Technology

2 倍做多納斯達克生物技術 ETF - ProShares

Defiance Daily Target 2X Short LLY ETF

2 倍做多 LLY ETF - Defiance

2 倍做多 LLY ETF - Direxion

禮來

1 倍做空 LLY ETF - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

諾和諾德公司

基因改革 ETF - ARK

2 倍做多 NVO ETF - Defiance

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

美國制藥 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

Compounder 公司起訴禮來和諾和諾德公司，指控他們壓制 GLP-1RA 的市場競爭